This is a routine option-exercise-and-sell pattern by two senior executives, the dollar amount is trivial relative to CYTK's $10B market cap. Per the sell-cluster literature, insider sales at this magnitude are non-predictive and likely driven by liquidity/tax planning. Monitor next 10-Q (due November 2026) for any change in commercial trajectory for aficamten, C-suite option-driven selling does not signal fundamental deterioration at this level.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 1 $71.40entry
- T+1 · 3mo ago +0.74%α +0.30% · $71.93
- T+5 · 2mo ago +3.80%α +3.71% · $74.11
- T+20 · 7w ago −7.69%α −7.80% · $65.91
- T+53 · todayOpen
- T+60 · in 8d Pending
Price Chart
How similar events traded
Executive Summary
CEO Robert Blum and EVP Andrew Callos each exercised and immediately sold vested stock options on the same day, totaling $1.23M in open-market sales at $70.24/share. While option exercises plus same-day sales are a common pattern for tax and diversification purposes, the simultaneous, lockstep action by C-suite executives warrants attention, especially given the $10B market cap and 89% analyst bullish consensus. Historically, sell clusters at this company have been non-predictive, and the $1.23M represents only ~0.01% of market cap, trivial relative to market depth.
Key Financial Metrics
Key Facts
- CEO Robert I. Blum sold 7,500 shares at $70.24 for $526,800 after exercising options at $10.60 and $0 (non-cash).
- EVP Andrew Callos sold 10,000 shares at $70.24 for $702,400 after exercising options at $0 and $23.26.
- Total open-market sales: $1.23M, representing ~0.01% of CYTK's $10.0B market cap.
- Both insiders sold on the same day (August 31, 2026) at the same price ($70.24), consistent with a coordinated 10b5-1 plan or post-exercise routine pattern.
- No open-market purchases were reported in the cluster window.
Financial Impact
$1.23M in insider sales, less than 0.01% of market cap, immaterial from a capital allocation standpoint.
Risk Factors
- If future sales at higher volumes emerge from additional C-suite members, that would escalate the signal.
- Continued insider sales without open-market purchases could dampen sentiment among retail investors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1788210112298 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $56.13 +4.41% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $56.13 +0.00% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $56.13 +1.04% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $56.13 −11.75% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $56.13 −9.51% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers